BioSpace News Archive

Daily Burn Debuts an App just for High Intensity Interval Training: HIIT Workouts by Daily Burn

Mr. Kilcoyne brings more than 30 years of experience in the medical device market to the Cerus Endovascular Board.

Syncroness is excited to announce that Vice President of Engineering, Todd Mosher, will present Syncroness’ cutting-edge Agile methodology for space hardware design at this year’s AIAA Space Forum on September 18, 2018.

The 2019 Bridging Clinical Research & Clinical Health Care Collaborative will convene March 4–5, 2019, at the National Academy of Sciences in Washington, D.C.

Global Healthcare Exchange, LLC (GHX) today announced that it has launched a mobile-enhanced Vendormate Credentialing application with new geolocation service capabilities.

LEO Science & Tech Hub, the Boston-based R&D innovation unit of LEO Pharma, has announced a new partnership with Epicore Biosystems focused on exploring the use of a non-invasive, wearable sweat sensor to measure prognostic biomarkers in real time, monitor patient response and inform treatment decisions.

Analytics 4 Life, a digital health company dedicated to improving existing diagnostic pathways, today announced that clinical data will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 scientific symposium.

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, today announced that the Company has received a $1.6 million grant

FDA & USDA announced they have approved Phageguard-E as a “GRAS” (Generally Recognized as Safe) food processing aid against E.coli O157.

Contego Medical announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the first filter-based Integrated Embolic Protection (IEP) device, the Paladin® Carotid PTA Balloon System. Contego Medical is developing and commercializing a suite of next-generation devices that address unmet needs in neurovascular, coronary and peripheral vascular disease.